The Latest Breaking News from Biogen

Biogen has recently lagged behind the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on the stock's long-term growth potential.

Missed out on this year's top S&P 500 stocks? Analysts are already offering up their ideas on which stocks will rule in 2025.

Providing a diverse range of perspectives from bullish to bearish, 19 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months.

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

The stock market retreated this week amid earnings from Microsoft, Amazon, Meta, Apple, Google and many more, along with preelection jitters.

Biogen stock dipped Wednesday despite an unexpected boost from its new Alzheimer's drug, Leqembi, and an earnings guidance hike.

Biogen will release its third-quarter earnings this month, and analysts anticipate a double-digit profit dip.

Bioverativ formed a perfect double bottom, a key chart pattern for growth stock hunters, and broke out ahead of its big 61% gain on news it's being bought by Sanofi.

Biogen has underperformed the Dow over the past year, but analysts are moderately optimistic about the stock’s prospects.

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.